DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Outcomes of patients with technically resectable stage III non-small cell lung cancer treated with concurrent chemoradiation followed by durvalumab consolidation.

Meanwhile, French biotech Sensorion is running a phase 1/2 trial of its SENS-501 (OTOF-GT) candidate and has a candidate for GJB2-related hearing loss in preclinical development.

The biotech acquired DB-OTO as part of its $109 million takeover of Decibel Therapeutics earlier this year, and is also working on candidates for deafness caused by mutations in the GJB2 and STRC ...

SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...

Single-cell analysis explores GJB2-mediated interactions in cancer-associated pericyte subgroups that promote lymph node metastasis in lung adenocarcinoma.

Additionally, the scientists noted a significant incidence of variants—also called loss-of-function variants—in the GJB2 and ABCC2 genes, which are associated with hearing loss and chronic liver ...

Physical examination and histopathology image. (A) Bilateral linear keratotic lesions at dorsum of metacarpophalangeal joints and right wrist. (B) Bilateral palmar keratoderma with “honeycomb” ...